PubMed
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)
Sikiric et al., 2018
Healing & RecoveryResearch OnlyC
BPC-157 Stable
BPC-157 Stable Capsule
Stabilized oral BPC-157 variant marketed for GI-focused research protocols.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- C
- Experience
- 55
- Activity
- 47
Overall check-ins
Trackers & reports
Overview
About BPC-157 Stable
Stabilized oral BPC-157 variant marketed for GI-focused research protocols.
- Category
- Healing & Recovery
- Regulatory status
- Research Only
- Also known as
- BPC-157 Stable Capsule
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 100% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 200–600 mcg
200–400
4
400–600
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (4)
Source
PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric et al., 2018
PubMed
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Seiwerth et al., 2021
PubMed
Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy
Sikiric et al., 2020
Tools
Explore more
Explore
More ways to learn about BPC-157 Stable from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about BPC-157 Stable?
This page summarizes 6 anonymized self-reports from PeptIQ users who track BPC-157 Stable, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for BPC-157 Stable?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for BPC-157 Stable?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is BPC-157 Stable safe to use?
This wiki does not assess safety or recommend use. BPC-157 Stable is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of BPC-157 Stable?
Research, primarily in animal models, suggests BPC-157 Stable may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of BPC-157 Stable?
BPC-157 Stable is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified BPC-157 Stable as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of BPC-157 Stable?
The safety and effectiveness of BPC-157 Stable have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on BPC-157 Stable?
While there are over 200 published studies on BPC-157 Stable, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source